2016
DOI: 10.18632/aging.101117 View full text |Buy / Rent full text
|
|

Abstract: Numerous studies suggest that rapamycin treatment promotes insulin resistance, implying that rapamycin could have negative effects on patients with, or at risk for, type 2 diabetes (T2D). New evidence, however, indicates that rapamycin treatment produces some benefits to energy metabolism, even in the context of T2D. Here, we survey 5 mouse models of T2D (KK, KK-Ay, NONcNZO10, BKS-db/db, TALLYHO) to quantify effects of rapamycin on well-recognized markers of glucose homeostasis within a wide range of T2D envir… Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
2
37
0

Publication Types

Select...

Relationship

0
0

Authors

Journals